Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
A phase 3 trial of 18F-MFBG in neuroblastoma, run by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), active and no longer recruiting.
Overview
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma is a phase 3 interventional study registered as NCT04724369 by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), with 43 participants enrolled, started 2021-11-18 and due to reach its primary completion in 2026-07-30. Interventions recorded: 18F-MFBG.
Similar pages
not linked directly; found by shared links- TrialTest-retest Evaluation of [18F]F-AraG PET
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography) and the tag pipeline.
- TrialImaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Shares Fluorine-18 and the tag pipeline.
- AgentPSMA-1007 F-18
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialUsing 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Shares Fluorine-18 and the tag pipeline.
- Trial[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Fluorine-18 and the tag pipeline.